

**Amendments to the Claims**

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1. (Currently Amended) An isolated monoclonal antibody that specifically binds to an amino acid sequence depicted at SEQ ID NO:1 ~~or an immunogenic fragment thereof~~.
- 2-4. (Canceled)
5. (Original) The antibody of claim 1 wherein the antibody is covalently attached to a compound.
6. (Original) The antibody of claim 5 wherein the compound is a chemotherapeutic agent.
7. (Original) The antibody of claim 5 wherein the compound is a detectable marker.
8. (Original) The antibody of claim 7 wherein the detectable marker is a fluorescent marker.
9. (Original) The antibody of claim 1 wherein the antibody specifically binds to an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1.
10. (Original) A composition comprising an antibody of claim 1.
11. (Original) The composition of claim 10 further comprising a pharmaceutically acceptable carrier.
12. (Currently Amended) A method for making an antibody comprising administering to an animal a polypeptide comprising an amino acid sequence depicted at amino acids 13-27 of SEQ

ID NO:1 or an immunogenic fragment thereof, and isolating the antibody from the animal, wherein the isolated antibody specifically binds to amino acids 13-27 of SEQ ID NO:1 the ~~amino acid sequence~~.

13. (Previously Presented) The method of claim 12 wherein the polypeptide or immunogenic fragment thereof is covalently attached to a carrier polypeptide.

14. (Currently Amended) A method for making an antibody comprising:  
administering to an animal a polypeptide comprising an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1 or an immunogenic fragment thereof;  
obtaining from the animal a cell that produces the antibody;  
making a monoclonal antibody-producing hybridoma using the cell; and  
isolating a monoclonal antibody from the monoclonal antibody-producing hybridoma, wherein the isolated monoclonal antibody specifically binds to amino acids 13-27 of SEQ ID NO:1 the ~~amino acid sequence~~.

15. (Original) A polyclonal antibody produced by a method of claim 12.

16. (Original) A monoclonal antibody produced by a method of claim 14.

17-28. (Canceled)

29. (Previously Presented) A method for detecting a polypeptide comprising:  
providing a cell;  
analyzing the cell for a polypeptide, wherein the polypeptide has a molecular weight of 36 kDa as measured following electrophoresis on a sodium dodecyl sulfate (SDS)-polyacrylamide gel, and is recognized by an isolated antibody that specifically binds to a polypeptide comprising the amino acid sequence depicted in SEQ ID NO:1; and

determining whether the cell expresses the polypeptide;

wherein analyzing the cell for a polypeptide comprises contacting the cell with an antibody that specifically binds to the amino acid sequence depicted at SEQ ID NO:1 or an immunogenic fragment thereof, and detecting the bound antibody.

30. (Original) The method of claim 29 wherein the cell is *ex vivo*.

31. (Original) The method of claim 30 wherein the cell is a tumor cell.

32. (Original) The method of claim 31 wherein the tumor is a breast tumor.

33. (Original) The method of claim 29 wherein the cell is *in vivo*.

34. (Previously Presented) The method of claim 33 wherein the cell is a tumor cell.

35. (Previously Presented) The method of claim 34 wherein the tumor is a breast tumor.

36. (Canceled)

37. (Previously Presented) The method of claim 29 wherein the antibody is covalently attached to a detectable marker.

38. (Previously Presented) The method of claim 37 wherein the detectable marker is a fluorescent marker.

39-51. (Canceled)

52. (Previously Presented) A kit comprising an isolated monoclonal antibody that specifically binds to an amino acid sequence depicted at SEQ ID NO:1 or an immunogenic fragment thereof, and a packaging material.
53. (Previously Presented) The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a humanized monoclonal antibody.
54. (Previously Presented) The antibody of claim 53 wherein the antibody is covalently attached to a compound.
55. (Previously Presented) The antibody of claim 54 wherein the compound is a chemotherapeutic agent.
56. (Previously Presented) The antibody of claim 54 wherein the compound is a detectable marker.
57. (Previously Presented) The antibody of claim 56 wherein the detectable marker is a fluorescent marker.
58. (Previously Presented) The antibody of claim 53 wherein the antibody specifically binds to an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1.
59. (Previously Presented) A composition comprising an antibody of claim 53.
60. (Previously Presented) The composition of claim 59 further comprising a pharmaceutically acceptable carrier.

61. (Previously Presented) The method of claim 29 wherein the isolated antibody comprises a monoclonal antibody.

62. (Previously Presented) The method of claim 61 wherein the monoclonal antibody comprises a humanized monoclonal antibody.

63. (Previously Presented) The kit of claim 52 wherein the monoclonal antibody comprises a humanized monoclonal antibody.